Mizuho Securities analyst Salim Syed has maintained their bullish stance on KURA stock, giving a Buy rating today.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Salim Syed has given his Buy rating due to a combination of factors surrounding Kura Oncology’s recent trial outcomes and strategic plans. The company’s Phase 2 trial, KOMET-001, successfully achieved its primary endpoint, showing promising CR/CRh rates. Although specific data details are not publicly available until a major medical conference in 2025, the trial’s results suggest that the outcomes are within an acceptable range for potential approval. Moreover, safety and tolerability align with prior findings, indicating a stable profile for the drug.
In addition to these developments, Kura Oncology is aligned with the FDA on using a surrogate endpoint for potential accelerated approval in their KOMET-017 trials. This alignment signifies a strategic path towards regulatory approval, supported by promising preliminary data from previous trials. The company’s ability to adapt trial designs based on real-world data further strengthens the potential for successful outcomes. These factors collectively underscore the positive outlook and justify the Buy rating for Kura’s stock.
According to TipRanks, Syed is an analyst with an average return of -5.7% and a 39.19% success rate. Syed covers the Healthcare sector, focusing on stocks such as Kura Oncology, BridgeBio Pharma, and Syndax Pharmaceuticals.
In another report released today, JMP Securities also maintained a Buy rating on the stock with a $28.00 price target.